ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç°º°, ÄÄÆ÷³ÍÆ®º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2024-2031³â)
Patient Blood Management Market Size, Share, Growth Analysis, By Product (Instruments, Blood Processing Devices), By Component (Whole Blood, Blood Components), By End User, By Region - Industry Forecast 2024-2031
ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 137¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 146¾ï 6,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â 239¾ï ´Þ·¯·Î ¼ºÀåÇϸç, ¿¹Ãø ±â°£(2025-2032³â)ÀÇ CAGRÀº 6.30%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸®(PBM) ½ÃÀåÀº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¼ö¼ú Áõ°¡, PBMÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿¡ ÈûÀÔ¾î °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ Àü·«Àû Á¢±Ù ¹æ½ÄÀº ¼öÇ÷ÀÌ ÇÊ¿äÇÑ È¯ÀÚÀÇ Ä¡·á¸¦ °ÈÇÏ°í ±Ã±ØÀûÀ¸·Î °á°ú¸¦ °³¼±ÇÏ°í ¼öÇ÷¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÃÖ¼ÒÈÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ½ÉÇ÷°ü Áúȯ, ¾Ï, Ç÷¾× Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀº ¼öÇ÷ÀÌ ÇÊ¿äÇÑ ¼ö¼úÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº °¨¿° ¹× ¸é¿ª ¹ÝÀÀ°ú °°Àº °ü·Ã À§ÇèÀ» ÁÙÀ̱â À§ÇØ PBM Àü·«À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â ¼ö¼ú °á°ú °³¼±°ú ÇÕº´Áõ °¨¼Ò¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, PBM ¼Ö·ç¼Ç¿¡ ´ëÇÑ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼öÇ÷À» ´ëüÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ´ë¾È¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°è¿¡¼ PBM µµÀÔÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
¸ñÂ÷
¼·Ð
- Á¶»çÀÇ ¸ñÀû
- Á¶»ç ¹üÀ§
- Á¤ÀÇ
Á¶»ç ¹æ¹ý
- Á¤º¸ Á¶´Þ
- 2Â÷ µ¥ÀÌÅÍ¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
- ½ÃÀå ±Ô¸ð ¿¹Ãø
- ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ
°³¿ä
- ¼¼°è ½ÃÀå Àü¸Á
- °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
- ºÎ¹®º° ±âȸ ºÐ¼®
½ÃÀå ¿ªÇаú Àü¸Á
- ½ÃÀå °³¿ä
- ½ÃÀå ±Ô¸ð
- ½ÃÀå ¿ªÇÐ
- ÃËÁø¿äÀΰú ±âȸ
- ¾ïÁ¦¿äÀΰú °úÁ¦
- PorterÀÇ »ê¾÷ ºÐ¼®
ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®
- ÁÖ¿ä ¼º°ø ¿äÀÎ
- °æÀïÀÇ Á¤µµ
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ½ÃÀå ¿¡ÄڽýºÅÛ
- ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
- PESTEL ºÐ¼®
- °Å½Ã°æÁ¦ ÁöÇ¥
- ¹ë·ùüÀÎ ºÐ¼®
- °¡°Ý ºÐ¼®
ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð : Á¦Ç°º°
- ½ÃÀå °³¿ä
- ±â±â
- Ç÷¾× ó¸® ±â±â
- ¼öÇ÷ ±â±â
- ¾ÆÆä·¹½Ã½º ±â°è
- ¼¼Æ÷ ±¸Á¦ ½Ã½ºÅÛ
- Ç÷¾× ¹è¾ç ½ºÅ©¸®´× ±â±â
- ÀÚµ¿ Ç÷¾× ¹è¾ç ½Ã½ºÅÛ
- Áö¿ø Àåºñ
- Áø´Ü ¹× °Ë»ç±â±â
- ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ
- Ç÷¾× ºÐ¼®±â
- Ç÷¾×Çü °Ë»ç ºÐ¼®±â
- Â÷¼¼´ë ½ÃÄö½Ì(NGS) Ç÷§Æû
- ±âŸ
- Ç÷¾× º¸Á¸ ±â±â
- ¾×¼¼¼¸®
- ÁÖ»ç±â¿Í ¹Ù´Ã
- ¹ÙÀ̾˰ú Æ©ºê
- Ç÷¾× ¹é
- ±âŸ ¾×¼¼¼¸®
- ½Ã¾à°ú ŰƮ
- ¹è¾ç ¹Ìµð¾î
- Ç÷¾×Çü ÆÇÁ¤ ½Ã¾à
- ½½¶óÀÌµå ¿°»ö
- ¾î¼¼ÀÌ Å°Æ®
- ±âŸ
- ¼ÒÇÁÆ®¿þ¾î
- Ç÷¾×ÀºÇà ¹× ¼öÇ÷ ¼ÒÇÁÆ®¿þ¾î
- ±âŸ
ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð : ÄÄÆ÷³ÍÆ®º°
ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº°
ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´ Áö¿ª
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- GCC ±¹°¡
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°æÀï Á¤º¸
- »óÀ§ 5»çÀÇ ºñ±³
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
- ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
- ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
- ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ °³¿ä
- ȸ»ç °³¿ä
- Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
- ºÎ¹®º° Á¡À¯À² ºÐ¼®
- ¸ÅÃâÀÇ Àü³â´ëºñ ºñ±³(2022-2024³â)
ÁÖ¿ä ±â¾÷ °³¿ä
- Haemonetics Corporation(USA)
- Macopharma(France)
- Terumo Corporation(Japan)
- B. Braun SE(Germany)
- Grifols, S.A.(Spain)
- Asahi Kasei Corporation(Japan)
- BioMerieux SA(France)
- LivaNova PLC(UK)
- Fresenius Kabi AG(Germany)
- Roche Holding AG(Switzerland)
- Abbott Laboratories(USA)
- Bio-Rad Laboratories, Inc.(USA)
- Danaher Corporation(USA)
- Siemens Healthineers(Germany)
- Johnson & Johnson(USA)
- Medtronic plc.(Ireland)
- BD(Becton, Dickinson and Company)(USA)
- Cardinal Health(USA)
- Teleflex Incorporated(USA)
- Stryker Corporation(USA)
°á·Ð°ú ±ÇÀå»çÇ×
KSA
Patient Blood Management Market size was valued at USD 13.79 Billion in 2023 and is poised to grow from USD 14.66 Billion in 2024 to USD 23.9 Billion by 2032, growing at a CAGR of 6.30% during the forecast period (2025-2032).
The global patient blood management (PBM) market is on a robust growth trajectory, fueled by rising chronic disease prevalence, an uptick in surgical procedures, and heightened awareness of PBM benefits. This strategic approach aims to enhance care for patients needing blood transfusions, ultimately improving outcomes and minimizing transfusion reliance. Chronic diseases like cardiovascular disorders, cancer, and blood disorders are major contributors to surgical needs, intensifying transfusion requirements. However, healthcare providers are increasingly implementing PBM strategies to mitigate associated risks such as infections and immune reactions. This shift emphasizes improving surgical results and reducing complications, propelling market demand for PBM solutions. Furthermore, awareness of innovative alternatives to transfusions is increasingly promoting the adoption of PBM practices on a global scale.
Top-down and bottom-up approaches were used to estimate and validate the size of the Patient Blood Management market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Patient Blood Management Market Segmental Analysis
Global Patient Blood Management Market is segmented by product, component, end user and region. Based on product, the market is segmented into instruments, blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, blood storage devices, accessories, syringes & needles, vials & tubes, blood bags, other accessories, reagents and kits, culture media, blood typing reagents, slide staining, assay kits, others, software, blood bank and transfusion software and others. Based on component, the market is segmented into whole blood and blood components. Based on end user, the market is segmented into hospitals and blood banks. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Patient Blood Management Market
The Patient Blood Management market is driven by significant advancements in transfusion medicine, which have transformed the landscape of blood management practices. Innovations in techniques and technologies have greatly enhanced the safety, efficiency, and effectiveness of blood transfusions. As a result, healthcare providers are increasingly embracing patient blood management strategies to optimize patient outcomes. These developments not only reduce the risks associated with transfusions but also foster a greater understanding of the importance of prudent blood usage. Consequently, the ongoing evolution in transfusion medicine is playing a pivotal role in propelling the growth of the Patient Blood Management market.
Restraints in the Patient Blood Management Market
The Patient Blood Management market faces several restraints, primarily due to the challenges associated with altering established transfusion practices. Transitioning towards these new management strategies requires a significant shift away from traditional methods and medical standards. This shift can be hindered by resistance to change from healthcare professionals, as well as the need to accommodate individual physician preferences. Moreover, ensuring that adequate training and education are provided to facilitate understanding and acceptance of these innovative practices poses additional hurdles. As a result, these factors collectively impede the broader implementation and acceptance of patient blood management methodologies in clinical settings.
Market Trends of the Patient Blood Management Market
In the global Patient Blood Management market, a notable trend is the heightened emphasis on personalized and evidence-based transfusion practices, driven by a growing awareness of the risks associated with indiscriminate blood use. Healthcare providers are increasingly adopting tailored transfusion strategies that align with individual patient needs and clinical conditions, steering away from the traditional one-size-fits-all approach. This shift not only aims to enhance patient safety by reducing the likelihood of transfusion reactions and infections but also seeks to lower healthcare costs through optimized blood utilization. Consequently, hospitals and healthcare systems are investing in technologies and training that support this patient-centric model, indicating a transformational shift in blood management practices.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Patient Blood Management Market Size by Product & CAGR (2025-2032)
- Market Overview
- Instruments
- Blood Processing Devices
- Centrifuge
- Blood Cell Processors
- Blood Transfusion Devices
- Apheresis Machines
- Cell Salvage Systems
- Blood Culture Screening Devices
- Automated Blood Culture Systems
- Supporting Equipment
- Diagnostic & Testing Instruments
- Polymerase Chain Reaction
- Hematology Analyzer
- Blood Grouping Analyzers
- Next-Generation Sequencing (Ngs) Platforms
- Others
- Blood Storage Devices
- Accessories
- Syringes & Needles
- Vials & Tubes
- Blood Bags
- Other Accessories
- Reagents And Kits
- Culture Media
- Blood Typing Reagents
- Slide Staining
- Assay Kits
- Others
- Software
- Blood Bank And Transfusion Software
- Others
Global Patient Blood Management Market Size by Component & CAGR (2025-2032)
- Market Overview
- Whole Blood
- Blood Components
Global Patient Blood Management Market Size by End User & CAGR (2025-2032)
- Market Overview
- Hospitals
- Blood Banks
Global Patient Blood Management Market Size & CAGR (2025-2032)
- North America (Product, Component, End User)
- Europe (Product, Component, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product, Component, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product, Component, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Product, Component, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Macopharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- B. Braun SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Asahi Kasei Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LivaNova PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc. (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BD (Becton, Dickinson and Company) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cardinal Health (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teleflex Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stryker Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations